All In Biotech

Drug Trial Radar · NCT02156674

Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome

Study of Administration of Intravenous Naglazyme® Following Allogeneic Transplantation for Maroteaux-Lamy Syndrome

Last checked: Nov 20, 2026Latest source record: Dec 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

1

Actual

Start

Jan 26, 2016

Primary completion

Dec 1, 2019

Study completion Dec 1, 2019

Sponsor

Lead sponsor
Masonic Cancer Center, University of MinnesotaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
BioMarin Pharmaceutical
First posted
Jun 5, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 3 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single center study in which Naglazyme® will be given weekly for two years in patients with Maroteaux-Lamy syndrome, also known as mucopolysaccharide VI (MPS VI), who have previously been treated with an allogeneic transplant.

Conditions

  • Maroteaux-Lamy Syndrome

Interventions

  • Naglazyme®Drug

    1 mg per kg of body weight administered once weekly as an intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Urinary Glycosaminoglycan (GAG) ExcretionTime frame: Baseline and 2 years
  2. Change in Distance TraveledTime frame: Baseline and 2 years
  3. Change in Neurocognitive AbilityTime frame: Baseline and 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Minnesota Medical Center, Fairview

    Minneapolis, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.